HD-SCA is our toolset to explore different phases of the disease at the single cell level. HD-SCA uses the ‘No-Cell-Left-Behind’ approach to identify rare cancer cells and then characterizes these cells by single cell genomics and single cell proteomics. Towards that end, we have established critical academic and public-private-partnerships. The ultimate goal is for our research to enable and motivate the necessary studies for clinical utility.
Click here for a video describing the approach used by HD-SCA.